Impact of Tacrolimus Daily Dose Limitation in Renal Transplant Recipients Expressing CYP3A5: A Retrospective Study

The pharmacokinetic variability of tacrolimus can be partly explained by CYP3A5 activity. Our objective was to evaluate a tacrolimus sparing policy on renal graft outcome according to CYP3A5 6986A>G genetic polymorphism. This retrospective study included 1114 recipients with a median follow-up of...

Descripción completa

Detalles Bibliográficos
Autores principales: Lenain, Rémi, Maanaoui, Mehdi, Hamroun, Aghilès, Larrue, Romain, Van Der Hauwaert, Cynthia, Gibier, Jean-Baptiste, Gnemmi, Viviane, Gomis, Sébastien, Labalette, Myriam, Broly, Franck, Hennart, Benjamin, Pottier, Nicolas, Hazzan, Marc, Cauffiez, Christelle, Glowacki, François
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8539387/
https://www.ncbi.nlm.nih.gov/pubmed/34683143
http://dx.doi.org/10.3390/jpm11101002

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8539387/
https://www.ncbi.nlm.nih.gov/pubmed/34683143
http://dx.doi.org/10.3390/jpm11101002

Ejemplares similares